Clinical Trial

Disease: Solid Tumor, Adult, (NCT03747965)

Disease info:

An abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumours may be benign (not cancer), or malignant (cancer). Different types of solid tumours are named for the type of cells that form them. Examples of solid tumours are sarcomas, carcinomas, and lymphomas. Leukemias (cancers of the blood) generally do not form solid tumours.

The word tumor does not always imply cancer. In discussing tumors that are malignant (cancerous), however, the term solid tumor is used to distinguish between a localized mass of tissue and leukemia.

Frequency:
More than 1.9 million new cancer cases are expected to be diagnosed in the US in 2023.
Official title:
Phase I Study of CRISPR-Cas9 Mediated PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning Regimen of Paclitaxel and Cyclophosphamide in Mesothelin Positive Multiple Solid Tumors
Who:

Contact

Name: Weidong Han, Dr

Phine: 86-10-13651392893

Email: hanwdrsw@sina.com

Sponsor:

Chinese PLA General Hospital

Partners:
Locations:

China, Beijing

Chinese PLA General Hospital, Beijing, Beijing, China, 100853

Study start:
Nov. 1, 2018
Enrollment:
10 participants
Gene editing method:
CRISPR-Cas9
Type of edit:
Gene knock-out
Gene:
Programmed cell death protein 1 (PD-1)
Delivery method:
Lentivirus (LV) - Ex-vivo
Trial link:
https://clinicaltrials.gov/ct2/show/record/NCT03747965
Other links:

LinkSolid Tumours FrequencyLinkSolid Tumours DefinitionLinkCRISPR-Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functionsLinkThe Role of Gene Editing Within CAR T-Cell Therapy Development - Interview with Professor Waseem Qasim

Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Unknown

Description

Multiple solid tumors have positive targets of mesothelin expressed on the surfaces of the tumor cells, the investigators use the technique of CRISPR-Cas9 to knocked out the PD-1 of the chimeric antigen receptor (CAR) T cells with the combination of Pretreatment by Paclitaxel and Cyclophosphamideto to effect the immuno-microenvironment around tumors.

  1. To evaluate the feasibility and safety of CRISPR-Cas9 mediated PD-1 gene-knocked out chimeric antigen receptor (CAR) T cells in patients with mesothelin positive multiple solid tumors.
  2. To evaluate the duration and in vivo persistence of transferred CAR-T cells.
  3. To observe and measure anti-tumor responses for patients with detectable mesothelin positive tumor lesions.
Last updated: Apr. 20, 2024
close
Search CRISPR Medicine